Remdesivir News and Research

RSS

SARS-CoV-2 genome signature leads to replicative advantage in presence of Remdesivir

A new study indicates that low-level resistance of SARS-CoV-2 to remdesivir is not widespread and dissimilar to other RNA viruses revealing evolutionary predictability of this pandemic virus.

22 Sep 2021

Antiviral compound RG10 acts via intracellular SARS-CoV-2-ER dynamics

A new study describes a small molecule referred to as RG10 that may have potent antiviral activity against SARS-CoV-2 in human cells.

16 Sep 2021

Phase I trial investigates using antiparasitic nitazoxanide for treatment of COVID-19

In a recent study, researchers investigate the possibility of using the thiazolide antiparasitic nitazoxanide for the treatment of COVID-19.

15 Sep 2021

A sweet pill to swallow: oral nucleoside analog of Remdesivir improved SARS-CoV-2 pathogenesis in mice

A new study focused on in vitro antiviral activity in various cell models and in vivo therapeutic efficacy of oral GS-621763 in a mouse model of SARS-CoV-2 pathogenesis.

15 Sep 2021

UGA research offers hope for a viable therapeutic to combat COVID-19

As COVID-19 cases continue to skyrocket across the U.S. and the world, few options are available for treating patients infected with the SARS-CoV-2.

11 Sep 2021

Potential pancoronavirus fusion inhibitors that are effective against SARS-CoV-2 variants

A new study successfully identifies a series of inhibitors that possesses pancoronavirus activity against SARS-CoV, SARS-CoV-2, and MERS-CoV.

7 Sep 2021

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

In a recent study, scientists attempt to understand persistent COVID-19 and its implications in patients with hematologic malignancies.

6 Sep 2021

Rheumatoid arthritis drug plus standard of care may reduce COVID-19 mortality for hospitalized patients

Hospitalized patients with COVID-19 who received the rheumatoid arthritis drug baricitinib, in combination with the standard of care including corticosteroids, died less often than those receiving only the standard of care, according to a study released this week in The Lancet Respiratory Medicine.

1 Sep 2021

COVID-19 associated mucormycosis cases in India

India continues to grapple with the coronavirus disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, the country has reported over one million new cases for the past 28 days.

31 Aug 2021

Coronavirus buildup in the lungs is likely behind high mortality rates

A buildup of coronavirus in the lungs is likely behind the steep mortality rates seen in the pandemic, a new study finds.

31 Aug 2021

Existing drugs block or reduce SARS-CoV2 infection in cells

Since the beginning of the pandemic, researchers worldwide have been looking for ways to treat COVID-19. And while the COVID-19 vaccines represent the best measure to prevent the disease, therapies for those who do get infected remain in short supply.

19 Aug 2021

Antiviral activity of lipid-modified remdesivir in comparison to common remdesivir

In new research, scientists evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2.

10 Aug 2021

Flavonoid-based inhibitors targeting SARS-CoV 3CL protease for the treatment of SARS-CoV-2 infection

A new study has explored a series of potential flavonoid inhibitors targeting 3CL protease of SARS-CoV.

9 Aug 2021

Scientists identify calpeptin as potential inhibitor of SARS-CoV-2

A team of US-based scientists has recently conducted a robust high-throughput screening to identify potential entry inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The screening identifies calpeptin as a potent and highly specific inhibitor of SARS-CoV-2 and its variants. The study is currently available on the bioRxiv* preprint server.

9 Aug 2021

New study describes SARS-CoV-2 ExoN enzyme that promotes antiviral resistance

A new study describes the structure of a crucial enzyme present in SARS-CoV-2.

8 Aug 2021

Could a plant metabolite in liverworts be a potent antiviral against SARS-CoV-2 and other RNA viruses?

A new study from the National Centre for Biotechnology and Medicinal Chemistry Institute suggests Mother Nature delivered — in the form of liverworts. They found that the bryophyte Marchantia polymorpha, also known as umbrella liverworts, could work as a potential antiviral treatment.

5 Aug 2021

Water-soluble vitamin E compounds directly inhibit SARS-CoV-2 replication and synergize with remdesivir

Researchers in the United States have shown that water-soluble derivatives of vitamin E (α-tocopherol) exhibit potent antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

15 Jul 2021